Technologies to tackle the growing problem (and opportunity) of obesity globally have been undervalued as a result of adverse judgments by the FDA and the market against fledgling obesity drugs. It has been said that nature abhors a vacuum and, by analogy, the market for obesity treatment, driven by increasing prevalence, rapidly emerging data on the multiplying and costly effects of obesity’s complications, abhors a lack of new treatment options.
Technologies to tackle the growing problem (and opportunity) of obesity globally have been undervalued as a result of adverse judgments by the FDA and the market against fledgling obesity drugs. It has been said that nature abhors a vacuum and, by analogy, the market for obesity treatment, driven by increasing prevalence, rapidly emerging data on the multiplying and costly effects of obesity’s complications, abhors a lack of new treatment options. Manufacturers of device options and pharmaceuticals have generally not taken regulatory setbacks as a sign that the opportunity has diminished.
We forecast a robust market over the coming decade (with specific short-term milestone expected to buttress this) for both devices and drugs for the clinical management of obesity. See our forecast of the aggregate and composite obesity treatment market below:
Source: Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019.”
